Amylyx Pharmaceuticals' (AMLX) Relyvrio Receives Approval from FDA
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
(Updated - September 29, 2022 4:47 PM EDT)
Amylyx Pharmaceuticals' (NASDAQ: AMLX) Relyvrio received approval from the FDA for treatment of amyotrophic lateral sclerosis in adults.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves AstraZeneca breast cancer drug Etcamah via accelerated path
- Roivant to present Phase 2 mosliciguat data at ERS Congress Sept. 8
- FDA accepts United Therapeutics' sNDA for Tyvaso to treat IPF
Create E-mail Alert Related Categories
Corporate News, FDA, Hot FDA NewsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
